PUBLIC COMPANY
save$CGTXCOGNITION THERAPEUTICS INC
$CGTXPurchase, NY, USupdated 21d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
- —Expanded Access Program for CT1812 (Zervimesine)
- phase2A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
- phase2A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
- phase2Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
- phase2Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
- phase2Effect of CT1812 Treatment on Brain Synaptic Density
- phase1Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects
Insider activity
source: SEC Form 4🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that